Single-cell transcriptional pharmacodynamics of trifluridine in a tumor-immune model

Sci Rep. 2022 Jul 13;12(1):11960. doi: 10.1038/s41598-022-16077-7.


Understanding the immunological effects of chemotherapy is of great importance, especially now that we have entered an era where ever-increasing pre-clinical and clinical efforts are put into combining chemotherapy and immunotherapy to combat cancer. Single-cell RNA sequencing (scRNA-seq) has proved to be a powerful technique with a broad range of applications, studies evaluating drug effects in co-cultures of tumor and immune cells are however scarce. We treated a co-culture comprised of human colorectal cancer (CRC) cells and peripheral blood mononuclear cells (PBMCs) with the nucleoside analogue trifluridine (FTD) and used scRNA-seq to analyze posttreatment gene expression profiles in thousands of individual cancer and immune cells concurrently. ScRNA-seq recapitulated major mechanisms of action previously described for FTD and provided new insight into possible treatment-induced effects on T-cell mediated antitumor responses.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Colorectal Neoplasms* / drug therapy
  • Colorectal Neoplasms* / genetics
  • Colorectal Neoplasms* / pathology
  • Frontotemporal Dementia* / drug therapy
  • Humans
  • Leukocytes, Mononuclear / metabolism
  • Pyrrolidines / pharmacology
  • Single-Cell Analysis
  • Thymine / pharmacology
  • Thymine / therapeutic use
  • Trifluridine / pharmacology
  • Trifluridine / therapeutic use


  • Pyrrolidines
  • Thymine
  • Trifluridine